Analysts Set Nurix Therapeutics, Inc. (NASDAQ:NRIX) Price Target at $30.54

09 Apr 2026, 01:58 by Teresa Graham · The Cerbat Gem

Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX – Get Free Report) have earned a consensus rating of “Moderate Buy” from the fifteen research firms that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating, thirteen have issued a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $30.5385.

A number of equities research analysts recently weighed in on NRIX shares. Morgan Stanley set a $36.00 price target on Nurix Therapeutics and gave the stock an “overweight” rating in a report on Thursday, January 8th. HC Wainwright restated a “buy” rating and issued a $32.00 price target on shares of Nurix Therapeutics in a report on Tuesday, March 24th. Wells Fargo & Company lowered their price target on Nurix Therapeutics from $30.00 to $29.00 and set an “overweight” rating on the stock in a report on Thursday, January 29th. Piper Sandler upped their price target on Nurix Therapeutics from $32.00 to $35.00 and gave the stock an “overweight” rating in a report on Thursday, January 29th. Finally, Needham & Company LLC restated a “buy” rating and issued a $26.00 price target on shares of Nurix Therapeutics in a report on Wednesday.

View Our Latest Report on NRIX

Nurix Therapeutics Trading Down 4.6%

Shares of NRIX stock opened at $15.60 on Monday. The company has a market cap of $1.61 billion, a price-to-earnings ratio of -5.13 and a beta of 1.97. The stock has a 50 day simple moving average of $15.72 and a 200-day simple moving average of $15.22. Nurix Therapeutics has a 12-month low of $8.18 and a 12-month high of $22.50.

Nurix Therapeutics (NASDAQ:NRIX – Get Free Report) last released its quarterly earnings results on Tuesday, April 14th. The company reported ($0.79) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.03). The firm had revenue of $6.25 million during the quarter, compared to analyst estimates of $14.25 million. Nurix Therapeutics had a negative return on equity of 57.51% and a negative net margin of 314.90%. On average, equities analysts forecast that Nurix Therapeutics will post -2.99 earnings per share for the current fiscal year.

Trending Headlines about Nurix Therapeutics

Here are the key news stories impacting Nurix Therapeutics this week:

Positive Sentiment: Nurix advanced NX-5948 into a Phase 3, randomized head‑to‑head study in CLL/SLL — a de‑risking step for a leading oral degrader and a clear potential long‑term value driver if the program reads out well. Nurix Advances NX-5948 Into Phase 3 Head-to-Head Battle in CLL/SLL
Positive Sentiment: Nurix is enrolling the Phase 2 DAYBreak CLL‑201 bexobrutideg trial intended to support accelerated approval in relapsed/refractory CLL — this could create nearer‑term regulatory and commercial optionality if the data are strong. Nurix Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
Positive Sentiment: Needham reaffirmed a Buy rating with a $26 price target (~66% above current levels), which may support investor demand if confidence in the clinical pipeline persists. Benzinga Coverage of Needham Rating
Neutral Sentiment: Company to present at an upcoming investor conference — provides management a forum to update analysts and investors but is unlikely to move the stock unless new data or guidance are announced. Nurix Therapeutics to Participate in Upcoming Investor Conference
Neutral Sentiment: Some headlines noted the stock briefly edged higher despite the Q1 miss, reflecting mixed intraday positioning and interest from buyers focused on clinical catalysts. Nurix Therapeutics shares edge higher despite Q1 earnings miss
Negative Sentiment: Q1 results missed expectations: GAAP loss of $0.79/sh vs. consensus ‑$0.76, revenue $6.25M well below $14.25M expected — signaling heavier near‑term cash burn and raising skepticism about short‑term revenue traction. Nurix Therapeutics, Inc. (NRIX) Reports Q1 Loss, Lags Revenue Estimates
Negative Sentiment: Analysts and coverage highlighted expanding losses and increased R&D investment, which could pressure the share price until clinical readouts or partnerships validate the spending. Nurix Therapeutics (NRIX) Stock Declines Amid Expanding Losses and R&D Investment

Insider Buying and Selling

In related news, CFO Houte Hans Van sold 3,661 shares of the company’s stock in a transaction that occurred on Friday, January 30th. The stock was sold at an average price of $16.60, for a total value of $60,772.60. Following the sale, the chief financial officer owned 45,427 shares in the company, valued at $754,088.20. This represents a 7.46% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Gwenn Hansen sold 4,895 shares of the company’s stock in a transaction that occurred on Friday, January 30th. The stock was sold at an average price of $16.60, for a total value of $81,257.00. Following the completion of the sale, the insider owned 83,672 shares in the company, valued at approximately $1,388,955.20. This represents a 5.53% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 7.40% of the company’s stock.

Institutional Investors Weigh In On Nurix Therapeutics

A number of large investors have recently bought and sold shares of the stock. Vanguard Group Inc. grew its holdings in Nurix Therapeutics by 32.5% during the 4th quarter. Vanguard Group Inc. now owns 5,949,512 shares of the company’s stock valued at $112,862,000 after buying an additional 1,460,736 shares during the last quarter. General Atlantic L.P. acquired a new stake in Nurix Therapeutics during the 4th quarter valued at $92,899,000. Morgan Stanley grew its holdings in Nurix Therapeutics by 115.9% during the 4th quarter. Morgan Stanley now owns 4,881,069 shares of the company’s stock valued at $92,594,000 after buying an additional 2,620,323 shares during the last quarter. Vestal Point Capital LP grew its holdings in Nurix Therapeutics by 35.0% during the 4th quarter. Vestal Point Capital LP now owns 4,690,000 shares of the company’s stock valued at $88,969,000 after buying an additional 1,215,000 shares during the last quarter. Finally, Baker BROS. Advisors LP grew its holdings in Nurix Therapeutics by 20.0% during the 4th quarter. Baker BROS. Advisors LP now owns 4,658,556 shares of the company’s stock valued at $88,373,000 after buying an additional 776,431 shares during the last quarter.

About Nurix Therapeutics

(Get Free Report)

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.